Evidence map›Paper›PMID 41904891›Full record

ArticleJHEP reports : innovation in hepatology2026

Molecular endoscopy with next-generation sequencing improves diagnosis of cholangiocarcinoma in patients with extrahepatic biliary strictures.

Anne-Cécile Brunac, Adrian Culetto, Hadrien Reboul, Karl Barange, Louis Buscail, Nadim Fares, Ronan Guillemin, Emily Alouani, David Grand, Solène Evrard and 3 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anne-Cécile BrunacDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France. Electronic address: brunac.annececile@iuct-oncopole.fr.
Adrian CulettoDepartment of Gastroenterology and Pancreatology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
Hadrien ReboulDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.
Karl BarangeDepartment of Hepatology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
Louis BuscailDepartment of Gastroenterology and Pancreatology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
Nadim FaresDepartment of Digestive Oncology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
Ronan GuilleminDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.
Emily AlouaniDepartment of Digestive Oncology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
David GrandDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.
Solène EvrardDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.
Céline BassetDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.
Jean-Marie PeronDepartment of Hepatology, Toulouse University Hospital, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, 31059, France.
Janick SelvesDepartment of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse University Hospital, 1 avenue Irène Joliot-Curie, 31059 Toulouse cedex 9, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsDifferentiating benign from malignant extrahepatic biliary strictures remains a diagnostic challenge, despite advances in sampling techniques and ancillary tests. Next-generation sequencing (NGS) may improve diagnostic performance and enable essential molecular profiling for malignancies. We aimed to assess the diagnostic performance of targeted NGS compared to cytohistology and fluorescence in situ hybridization (FISH), using samples exclusively collected via optimized single-operator cholangioscopy.

methodsWe prospectively enrolled 104 patients with extrahepatic biliary strictures or suspected cholangiocarcinoma. A definitive diagnosis was established through cytohistology and clinical follow-up. In total, 445 samples (265 brushings and 180 biopsies) were collected. Targeted DNA sequencing was performed using a custom-designed 50-gene panel. FISH was retrospectively performed in a subgroup of 42 patients. The diagnostic performance of all three modalities was compared.

resultsNGS achieved a sensitivity of 82.2% for malignancy, significantly higher than cytohistology alone (59.2%, p = 1.9x10

conclusionsThe combination of cytohistology and NGS significantly improves diagnostic performance for cholangiocarcinoma in patients with extrahepatic biliary strictures using specimens obtained via single-operator cholangioscopy. This approach also enables early molecular profiling of low-cellularity specimens and may reduce diagnostic delays while optimizing therapeutic decision-making. IMPACT AND IMPLICATIONS: Differentiating benign from malignant extrahepatic biliary strictures remains a major clinical challenge, justifying the need for more sensitive and specific diagnostic tools beyond conventional cytohistology. Our findings show that combining next-generation sequencing with cytohistology significantly improves diagnostic performance, enables early molecular profiling, and is easily applicable in clinical laboratories. These results are especially relevant for patients with suspected cholangiocarcinoma and patients with primary sclerosing cholangitis, where timely and accurate diagnosis is critical and often difficult. Integrating next-generation sequencing into routine diagnostic workflows could reduce diagnostic delays and guide therapeutic decisions in patients with biliary tract lesions.

Indexed as

CholangiocarcinomaERCPExtrahepatic biliary strictureNGSPrimary sclerosing cholangitis

Identifiers

PMID41904891
PMCPMC13058966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.